Join to View Full Profile
Rockville Pike# 8901Bethesda, MD 20889
Phone+1 301-295-4611
Fax+1 301-480-2788
Dr. Mascola is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Naval Medical Center (San Diego)Residency, Internal Medicine, 1987 - 1989- Naval Medical Center (San Diego)Internship, Internal Medicine, 1985 - 1986
Georgetown University School of MedicineClass of 1985
Certifications & Licensure
CA State Medical License 1987 - 2022
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2002
Publications & Presentations
PubMed
- Pharmacokinetics Analysis of Serum and Rectal Tissue Concentrations of a Pair of Anti-HIV Monoclonal Antibodies, VRC01 and VRC01LS, in Adults Without HIV.Yunda Huang, Lily Zhang, Maria P Lemos, Rena D Astronomo, Sandeep Narpala
Journal of Clinical Pharmacology. 2025-11-01 - Production of Clinical-Grade SARS-CoV-2 Spike Ferritin Nanoparticle Protein Immunogen by Transient Transfection.Agnes Hajduczki, William C Chang, Rafael De La Barrera, James F Wood, Wei-Hung Chen
Vaccines. 2025-10-09 - 4 citationsStructural and genetic basis of HIV-1 envelope V2 apex recognition by rhesus broadly neutralizing antibodies.Ryan S Roark, Rumi Habib, Jason Gorman, Hui Li, Andrew Jesse Connell
The Journal of Experimental Medicine. 2025-10-06
Journal Articles
- Evaluation of the mRNA-1273 Vaccine Against SARS-CoV-2 in Nonhuman PrimatesJohn R Mascola, The New England Journal of Medicine
- Monoclonal Antibodies for Prevention and Treatment of COVID-19John R Mascola, Myron S Cohen, JAMA
- Structure-Based Design of a Quadrivalent Fusion Glycoprotein Vaccine for Human Parainfluenza Virus Types 1–4John Mascola, MD, Proceedings of the National Academy of Sciences
- Join now to see all
Authored Content
- Epitope-Based Vaccine Design Yields Fusion Peptide-Directed Antibodies That Neutralize Diverse Strains of HIV-1June 2020
Press Mentions
NIAID Vaccine R&D Director Who Collaborated with Moderna on COVID-19 Vaccine to RetireFebruary 16th, 2022- Vaccine Makers Pursue Omicron-Targeted Shots That Health Officials Say Might Not Be NeededJanuary 14th, 2022
- Covid-19 Vaccine Makers Assess Omicron ResponseNovember 29th, 2021
- Join now to see all
Grant Support
- Isolation And Deep Sequencing Of Monoclonal Antiobodies Against HIVNational Institute Of Allergy And Infectious Diseases2011
- Determination Of The Neutralization Specificity In Broadly Neutralizing HIV SERANational Institute Of Allergy And Infectious Diseases2010–2011
- Preclinical Evaluation Of Neutralizing Antibodies Elicited By HIV-1 ImmunogensNational Institute Of Allergy And Infectious Diseases2009–2011
- Non-Human Primate Immunogenicity Studies Of HIV-1 ImmunogensNational Institute Of Allergy And Infectious Diseases2009–2011
- NON Human Primate Models Of SIV And HIV Immune ProtectionNational Institute Of Allergy And Infectious Diseases2009–2011
- Measurement Of HIV Neutralization Using Quantitative AssaysNational Institute Of Allergy And Infectious Diseases2009–2011
- Isolation Of Monoclonal Antiobodies Against HIVNational Institute Of Allergy And Infectious Diseases2009–2010
- Evaluation Of Antibody Specificities In Broadly Neutralizing HIV SERANational Institute Of Allergy And Infectious Diseases2009
- Measurement Of HIV Neutralization Using Quantitative AssaysNational Institute Of Allergy And Infectious Diseases2008
- Isolation Of Monoclonal Antiobodies Against HIVNational Institute Of Allergy And Infectious Diseases2008
- Evaluation Of Antibody Specificities In Broadly Neutralizing HIV SERANational Institute Of Allergy And Infectious Diseases2008
- Preclinical Evaluation Of Neutralizing Antibodies Elicited By HIV-1 ImmunogensNational Institute Of Allergy And Infectious Diseases2007–2008
- Non-Human Primate Immunogenicity Studies Of HIV-1 ImmunogensNational Institute Of Allergy And Infectious Diseases2007–2008
- NON Human Primate Models Of SIV And HIV Immune ProtectionNational Institute Of Allergy And Infectious Diseases2007–2008
- Measurement Of HIV Neutralization Using Flow Cytometric &Reporter Virus AssaysNational Institute Of Allergy And Infectious Diseases2007
- Non-Human Primate Immunogenicity Studies Of HIV-1 ImmunoNational Institute Of Allergy And Infectious Diseases2005–2006
- Measurement Of HIV Neutralization Using Flow CytometricNational Institute Of Allergy And Infectious Diseases2005–2006
- Macaque Studies Of Correlates Of HIV ProtectionNational Institute Of Allergy And Infectious Diseases2004–2006
- Preclinical Evaluation Of Neutralizing Antibodies ElicitNational Institute Of Allergy And Infectious Diseases2002–2006
- Evaluation Of Neutralizing Antibodies Elicited By HIV-1National Institute Of Allergy And Infectious Diseases2005
- Preclinical Evaluation Of HIV-1 Neutralizing AntibodiesNational Institute Of Allergy And Infectious Diseases2004
- Measurement Of HIV NeutralizationNational Institute Of Allergy And Infectious Diseases2004
- Immunogenicity Studies Of HIV-1 ImmunogensNational Institute Of Allergy And Infectious Diseases2004
- Optimizing Measurement Of HIV-1 Neutralization Using ANational Institute Of Allergy And Infectious Diseases2003
- Passive Antibody Protection In The Setting Of Active CELNational Institute Of Allergy And Infectious Diseases2002–2003
- Non-Human Primate Immunogenicity Studies Of DNA Prime, RNational Institute Of Allergy And Infectious Diseases2002–2003
- Optimizing Measurement Of HIV-1 Neutralization Using A FNational Institute Of Allergy And Infectious Diseases2002
- Passive Antibody Protection In SHIV Challenge ModelNational Heart, Lung, And Blood Institute1997–1999
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
